Glioma Clinical Trials

49 studies are recruiting for glioma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study of 177Lu-PSMA-617 in People With Gliomas

   The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07223034 on ClinicalTrials.gov

2. Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

   This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Lenox Hill Brain Tumor Center, New York, New York

   Run by

   Northwell Health

   See if you can join NCT05979064 on ClinicalTrials.gov

3. PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial

   The purpose of this research study is to see if a specific type of radiation therapy, called "proton pulsed reduced dose rate" or "PRDR radiotherapy" has any benefits at dose levels and number of fractions thought to be acceptable in earlier research studies. The researchers want to find out what e…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Miami Cancer Institute at Baptist Health, Inc., Miami, Florida

   Locations

   2 in total

   Run by

   Baptist Health South Florida

   See if you can join NCT06397560 on ClinicalTrials.gov

4. LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

   The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly diagnosed gliomas.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Maryland Proton Treatment Center, Baltimore, Maryland

   Locations

   5 in total

   Run by

   University of Maryland, Baltimore

   See if you can join NCT04699773 on ClinicalTrials.gov

5. Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

   The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Chan…

   Stage

   EARLY_Phase 1

   Ages

   1 to 21

   Site

   The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT05555550 on ClinicalTrials.gov

6. Non-invasive Glioma Characterization Through Molecular Imaging

   MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT03684109 on ClinicalTrials.gov

7. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

   This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   23 in total

   Run by

   Nested Therapeutics, Inc

   See if you can join NCT06326411 on ClinicalTrials.gov

8. A Study Utilizing Escitalopram in Glioma Patients

   Glioma is a cancer of glial cells, a class of tissue supporting neuronal function in the brain. As many as 85% of glioma patients experience cognitive impairment. This is not only from direct tumor involvement, but also from therapy such as cranial radiation and chemotherapy, which degrades neurona…

   Stage

   Phase 2

   Ages

   19 and older

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Run by

   University of Nebraska

   See if you can join NCT03728673 on ClinicalTrials.gov

9. ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

   This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-fr…

   Stage

   Phase 3

   Ages

   Any age

   Site

   FLENI Neurologia, Buenos Aires,

   Locations

   162 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT05580562 on ClinicalTrials.gov

10. Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

    Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT02800486 on ClinicalTrials.gov

11. Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

    This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cav…

    Stage

    Phase 1

    Ages

    1 to 26

    Site

    Seattle Children's Hospital, Seattle, Washington

    Run by

    Seattle Children's Hospital

    See if you can join NCT04185038 on ClinicalTrials.gov

12. All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

    This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune response.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    Stephen Bagley, MD, MSCE

    See if you can join NCT05345002 on ClinicalTrials.gov

13. Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

    This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery (resectable). One important predictor of the immune response is the presenc…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

    Run by

    Jonsson Comprehensive Cancer Center

    See if you can join NCT06650163 on ClinicalTrials.gov

14. Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma

    High grade gliomas (HGGs) are rapidly progressive brain tumors resulting in death for most patients between 6 months and 2 years after diagnosis. It is important for patients with HGG to discuss and document their wishes at the end of life. However, many of these patients experience early changes i…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Rochester, Rochester, New York

    Run by

    University of Rochester

    See if you can join NCT04543201 on ClinicalTrials.gov

15. NeuroPathways Intervention for Brain Tumor Patients

    This goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. This study was developed to help patients cope after a brain tumor diagnosis. The main question this study aims to answer is whether this intervention (which includ…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachusetts General Hospital Cancer Center, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05976490 on ClinicalTrials.gov

16. Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

    The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Henry Ford Health System, Detroit, Michigan

    Run by

    Henry Ford Health System

    See if you can join NCT05686798 on ClinicalTrials.gov

17. 18F-Fluciclovine PET-MRI in High-grade Glioma

    The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes th…

    Stage

    EARLY_Phase 1

    Ages

    1 to 21

    Site

    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

    Run by

    Children's Hospital of Philadelphia

    See if you can join NCT05553041 on ClinicalTrials.gov

18. Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

    The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring. WeThe reserchers are doing this study to see whether this advanced imaging is a safe treatme…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT00870129 on ClinicalTrials.gov

19. Tumor Treating Fields for the Treatment of Brainstem Gliomas

    This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields called tumor treating fields (TTFields), which interfere with ca…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Emory University/Winship Cancer Institute, Atlanta, Georgia

    Locations

    3 in total

    Run by

    Emory University

    See if you can join NCT05310448 on ClinicalTrials.gov

20. Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

    The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the adde…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    Rosy Njonkou Tchoquessi, Baltimore, Maryland

    Run by

    University of Maryland, Baltimore

    See if you can join NCT04772456 on ClinicalTrials.gov

21. Registering Genomics and Imaging of Tumors (ReGIT)

    This study is investigating how brain tumors might mutate over time, and whether new brain imaging tools like MRI and PET can predict these mutations.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Indiana University School of Medicine, Indianapolis, Indiana

    Run by

    Indiana University

    See if you can join NCT05386043 on ClinicalTrials.gov

22. ASCENT Intervention for Brain Tumor Patients

    The goal of this study is to refine and test a psychosocial intervention called ASCENT (ACT-based Supportive intervention for patients with CENTral nervous system tumors). This intervention was developed to help patients after being diagnosed with a brain tumor. The main question this study aims to…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachusetts General Hospital Cancer Center, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT06099743 on ClinicalTrials.gov

23. Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

    This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas

    Run by

    Cerenome

    See if you can join NCT05460507 on ClinicalTrials.gov

24. Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

    This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy tr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northshore University Hospital, Manhasset, New York

    Locations

    3 in total

    Run by

    Cerenome

    See if you can join NCT01906385 on ClinicalTrials.gov